BLSA

Bellevue Life Sciences Acquisition Corp was a special purpose acquisition company formed to identify and merge with a healthcare or life sciences business, with stated interest in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies. It was not itself an operating biotech, pharma, or healthcare product company and did not develop therapeutic programs. The company was listed on Nasdaq under the symbol BLSA at IPO and later used BLAC in connection with its later public-company history and business-combination process. Available sources indicate it ultimately completed a transaction tied to OSR Holdings rather than operating as an independent drug developer. For biotech landscape purposes, it should be classified as a healthcare-focused acquisition vehicle rather than a therapeutics company.